Exchange: NASDAQ·Updated 08:26 AM EDT
KYMR logo

KYMR Kymera Therapeutics Inc

$118.50
$0.31
(0.26%)
Pre-Market
Prev Close $118.81
Reported EarningsAug 5
Mkt Cap$9.88B
Vol1,102.00

About KYMR

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
46

Neutral Sentiment

How do you feel about KYMR?

Advertisement|Remove ads.